1
|
Alexander KE, Cooper BA, Paul SM, Yates P, Aouizerat BE, Miaskowski C. Phenotypic and molecular characteristics associated with various domains of quality of life in oncology patients and their family caregivers. Qual Life Res 2016; 25:2853-2868. [PMID: 27160108 DOI: 10.1007/s11136-016-1310-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/29/2016] [Indexed: 12/12/2022]
Abstract
PURPOSE Not all oncology patients and their family caregivers (FCs) experience the same quality of life (QOL). The purposes of this study were to identify latent classes of oncology patients (n = 168) and their FCs (n = 85) with distinct physical, psychological, social, and spiritual well-being trajectories from prior to through 4 months after the completion of radiation therapy and to evaluate for demographic, clinical, and genetic characteristics that distinguished between these latent classes. METHODS Using growth mixture modeling, two latent classes were found for three (i.e., physical, psychological, and social well-being) of the four QOL domains evaluated. RESULTS Across these three domains, the largest percentage of participants reported relatively high well-being scores across the 6 months of the study. Across these three QOL domains, patients and FCs who were younger, female, belonged to an ethnic minority group, had children at home, had multiple comorbid conditions, or had a lower functional status, were more likely to be classified in the lower QOL class. The social well-being domain was the only domain that had a polymorphism in nuclear factor kappa beta 2 (NFKB2) associated with latent class membership. Carrying one or two doses of the rare allele for rs7897947 was associated with a 54 % decrease in the odds of belonging to the lower social well-being class [OR (95 % CI) = .46 (.21, .99), p = .049]. CONCLUSIONS These findings suggest that a number of phenotypic and molecular characteristics contribute to differences in QOL in oncology patients and their FCs.
Collapse
Affiliation(s)
- Kimberly E Alexander
- School of Nursing, Queensland University of Technology, Victoria Park Road, Kelvin Grove, Brisbane, Australia
| | - Bruce A Cooper
- Department of Physiological Nursing, School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA
| | - Steven M Paul
- Department of Physiological Nursing, School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA
| | - Patsy Yates
- School of Nursing, Queensland University of Technology, Victoria Park Road, Kelvin Grove, Brisbane, Australia
| | | | - Christine Miaskowski
- Department of Physiological Nursing, School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA.
| |
Collapse
|
2
|
Alexander KE, Chambers S, Spurdle AB, Batra J, Lose F, O'Mara TA, Gardiner RA, Aitken JF, Clements JA, Kedda MA, Janda M. Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population. Qual Life Res 2015; 24:2183-93. [PMID: 25724697 DOI: 10.1007/s11136-015-0950-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/18/2015] [Indexed: 01/14/2023]
Abstract
PURPOSE Improved survival for men with prostate cancer has led to increased attention to factors influencing quality of life (QOL). As protein levels of vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1) have been reported to be associated with QOL in people with cancer, we sought to identify whether single-nucleotide polymorphisms (SNPs) of these genes were associated with QOL in men with prostate cancer. METHODS Multiple linear regression of two data sets (including approximately 750 men newly diagnosed with prostate cancer and 550 men from the general population) was used to investigate SNPs of VEGF and IGF-1 (10 SNPs in total) for associations with QOL (measured by the SF-36v2 health survey). RESULTS Men with prostate cancer who carried the minor 'T' allele for IGF-1 SNP rs35767 had higher mean Role-Physical scale scores (≥0.3 SD) compared to non-carriers (p < 0.05). While this association was not identified in men from the general population, one IGF-1 SNP rs7965399 was associated with higher mean Bodily Pain scale scores in men from the general population that was not found in men with prostate cancer. Men from the general population who carried the rare 'C' allele had higher mean Bodily Pain scale scores (≥0.3 SD) than non-carriers (p < 0.05). CONCLUSIONS Through identifying SNPs that are associated with QOL in men with prostate cancer and men from the general population, this study adds to the mapping of complex interrelationships that influence QOL and suggests a role for IGF-I in physical QOL outcomes. Future research may identify biomarkers associated with increased risk of poor QOL that could assist in the provision of pre-emptive support for those identified at risk.
Collapse
Affiliation(s)
- Kimberly E Alexander
- Institute of Health and Biomedical Innovation (IHBI), School of Nursing, Queensland University of Technology (QUT), Kelvin Grove, Brisbane, QLD, 4059, Australia,
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Longitudinal Study of Intestinal Symptoms and Fecal Continence in Patients With Conformal Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2011; 79:1373-80. [DOI: 10.1016/j.ijrobp.2010.01.033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2009] [Revised: 11/17/2009] [Accepted: 01/09/2010] [Indexed: 11/22/2022]
|
4
|
Geinitz H, Thamm R, Scholz C, Heinrich C, Prause N, Kerndl S, Keller M, Busch R, Molls M, Zimmermann FB. Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer. Strahlenther Onkol 2009; 186:46-52. [PMID: 20082188 DOI: 10.1007/s00066-009-2023-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2009] [Accepted: 09/30/2009] [Indexed: 01/27/2023]
Abstract
PURPOSE To prospectively assess quality of life (QoL) in patients receiving conformal radiation therapy (CRT) for prostate cancer. PATIENTS AND METHODS 78 men with definitive CRT for prostate cancer were entered into the study. Patients were assessed before CRT, at 40 and 60 Gy, and 2, 12 and 24 months after the end of treatment. QoL was assessed using the EORTC Quality of Life Questionnaire C30 and the prostate module PR25. Changes in mean QoL scores with time of >or= 10 points were considered clinically relevant. RESULTS Global QoL did not change statistically significant during CRT and was slightly above baseline levels during follow-up. CRT had a statistically significant negative short-term impact on role functioning, fatigue, and PR25 urinary symptoms. The scores recovered within 2 months to 1 year after CRT. Emotional functioning and social functioning scores slightly increased during and after CRT. Role functioning decreased by > 10 points at 60 Gy and urinary symptoms decreased by > 10 points at 40 and 60 Gy. All other differences were < 10 points. A high number of concomitant diseases and having no children were negative pretreatment predictors for long-term global QoL. CONCLUSION Definitive CRT for prostate cancer does not compromise global QoL during therapy and up to 2 years after treatment. It has a limited negative effect on role functioning, urinary symptoms and, to a lesser extent, on fatigue with restitution within 2 months to 1 year after treatment.
Collapse
Affiliation(s)
- Hans Geinitz
- Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany. .,Klinik und Poliklinik für Strahlentherapie und Radiologische Onkologie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Straße 22, 81675, München, Germany.
| | - Reinhard Thamm
- Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany
| | - Christian Scholz
- Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany
| | - Christine Heinrich
- Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany
| | - Nina Prause
- Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany
| | - Simone Kerndl
- Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany
| | - Monika Keller
- Psychooncology Section, Department of Psychosomatic and General Clinical Medicine, University Hospital, Heidelberg, Germany
| | - Raymonde Busch
- Institute of Medical Statistics and Epidemiology, Technische Universität München, München, Germany
| | - Michael Molls
- Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany
| | - Frank B Zimmermann
- Department of Radiotherapy and Radiooncology, Technische Universität München, München, Germany
| |
Collapse
|
5
|
Waldmann A, Rohde V, Bremner K, Krahn M, Kuechler T, Katalinic A. Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P). BMC Cancer 2009; 9:295. [PMID: 19698163 PMCID: PMC2739225 DOI: 10.1186/1471-2407-9-295] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2009] [Accepted: 08/23/2009] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The PORPUS-P is a short questionnaire for measuring prostate-specific quality of life (QoL), which was designed in Canada for use in prostate cancer (PC) patients. We aimed to generate a German version and compare PORPUS-P scores of German reference men from the general population, and German and Canadian patients with newly diagnosed PC who were scheduled to receive radical prostatectomy (RP) or radiotherapy (RT). METHODS The study sample consisted of 988 reference men, 121 German and 66 Canadian PC patients scheduled for RT, and 371 German and 68 Canadian PC patients scheduled for RP. All men completed the PORPUS-P (German postal questionnaire, Canada personal interview). Data were gathered from PC patients before the start of therapy. RESULTS Canadian patients were better educated than the German patients, and fewer were retired. Patients scheduled to receive RT were older and more were retired. German RT patients had lower D'Amico risk scores and pre-treatment Gleason scores than RP patients, and Canadian RT patients had higher pre-treatment PSA than RP patients. Urinary and sexual dysfunction were seen in PC patients (especially RT patients), but were also common in the German reference men. Crude mean PORPUS-P scores differed statistically significant between German RT and RP and Canadian RP and RT patients, with RT patients having higher QoL scores. The differences in age-adjusted mean PORPUS-P scores between reference men and RP patients were not clinically significant, while RT patients had (clinically) significantly lower scores than the reference men. CONCLUSION The German translation of the PORPUS-P appears to be a short and feasible tool for assessing prostate-specific QoL. Although we found a similar response pattern, Canadian and German PC patients scheduled to receive RT or RP rated their pre-treatment quality of life on different levels, which reveals the need for national reference data. Problems in several QoL domains exist before treatment, and differ between PC patients scheduled for RT and RP.
Collapse
Affiliation(s)
- Annika Waldmann
- Institute of Cancer Epidemiology, University Luebeck, Beckergrube 43-47, 23552 Luebeck, Germany.
| | | | | | | | | | | |
Collapse
|
6
|
Lips IM, van Gils CH, van der Heide UA, Kruger AEB, van Vulpen M. Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. BJU Int 2008; 103:762-7. [PMID: 18990145 DOI: 10.1111/j.1464-410x.2008.08117.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To evaluate the change in quality of life (QoL) 3 years after high-dose intensity-modulated radiotherapy (IMRT) using gold fiducial marker-based position verification in patients with locally advanced prostate cancer. PATIENTS AND METHODS Between October 2003 and November 2004, 95 patients with locally advanced prostate cancer were treated with 76 Gy IMRT with gold-fiducial marker-based position verification. Before treatment (baseline) and 1, 6 and 36 months after RT the QoL was measured using the RAND-36, the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ-C30(+3)) and the prostate tumour-specific module (EORTC QLQ-PR25). Changes in QoL with time of > or =10 points were considered clinically relevant. RESULTS After 3 years there was a statistically significant improvement in QoL for emotional role restriction and functioning, change in health, mental health and insomnia, compared with baseline. Emotional role restriction increased by >10 points and was therefore clinically relevant, while all other differences were of <10 points. There was a statistically significant deterioration of QoL after 3 years in physical and cognitive functioning, bowel symptoms/function and sexual activity. Only the sexual activity QoL score changed by 12 points and was therefore the only meaningful deterioration in QoL at 3 years after treatment. CONCLUSION IMRT and accurate position verification provide the possibility to deliver a high irradiation dose to the prostate without clinically relevant deterioration in long-term QoL, except for a persistent decrease in sexual activity score.
Collapse
Affiliation(s)
- Irene M Lips
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
| | | | | | | | | |
Collapse
|
7
|
Tärnhuvud M, Wändel C, Willman A. Nursing interventions to improve the health of men with prostate cancer undergoing radiotherapy: a review. Eur J Oncol Nurs 2007; 11:328-39. [PMID: 17409023 DOI: 10.1016/j.ejon.2007.01.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2006] [Revised: 01/18/2007] [Accepted: 01/24/2007] [Indexed: 11/18/2022]
Abstract
The aim of this study was to investigate what nurses do to improve the health of men who are receiving radiotherapy treatment due to prostate cancer. The method was a literature review using a systematic approach. The Cochrane Library, Medline and CINAHL databases were used in a search that covered the period from January 1994 to April 2006. The screening of 200 abstracts resulted in 14 articles corresponding to the research question, which were assessed according to scientific quality. Two independent reviewers performed the screening and quality assessment process using specific protocols. Two themes emerged: nurse-led care related to radiotherapy treatment and patients' experiences of radiotherapy treatment. The results show that there is strong scientific support for nurse-led follow-up care aimed at assisting patients by means of providing information on how to manage side effects (evidence grade A). In addition, there is moderate scientific support for the need to ensure that this information is structured, objective and concrete and that it can be provided by means of audiotapes or over the phone (evidence grade B) as well as weak scientific support for reporting patients' experiences of radiotherapy treatment (evidence grade C).
Collapse
Affiliation(s)
- Marie Tärnhuvud
- Department of Oncology, Malmö University Hospital, S-205 02 Malmö, Sweden.
| | | | | |
Collapse
|
8
|
Korfage IJ, de Koning HJ, Habbema JDF, Schröder FH, Essink-Bot ML. Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls? BJU Int 2007; 99:801-6. [PMID: 17233804 DOI: 10.1111/j.1464-410x.2006.06707.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To determine how men treated for localized prostate cancer and who had permanent side-effects, and healthy controls, would value five descriptions of health states associated with side-effects of treatment for localized prostate cancer, hypothesising that patients would value the health states as less detrimental than men with no prostate cancer. PATIENTS, SUBJECTS AND METHODS In previous research, patients with prostate cancer reported high generic quality-of-life scores after primary treatment, despite side-effects; it was suggested that these patients accepted the side-effects, i.e. urinary, bowel and sexual dysfunction, as 'part of the bargain' because they felt they were saved from a life-threatening disease. Thus, we asked 54 men who had been treated for localized prostate cancer and had permanent side-effects, and 53 healthy controls, to value five descriptions of health states. All respondents valued all descriptions using two valuation methods, a visual analogue scale (VAS, range 0-100) and time trade-off (TTO, range 0-1). The respondent functioning was assessed using the EuroQol-5D, completed with items on urinary, bowel and sexual function. RESULTS Patients and healthy controls had similar valuations for nine of the 10 comparisons (five health states by two methods). Valuations in both groups resulted in the same ranking order of states on the TTO and one exchange in rank order on the VAS. CONCLUSIONS When asked to value five health states associated with side-effects of treatment for localized prostate cancer, there was no difference in the valuation of erectile, urinary and bowel dysfunction between patients with permanent side-effects after treatment and healthy controls. More likely explanations for the high generic quality-of-life scores after primary treatment for prostate cancer are a response shift and insensitivity of generic health-related quality-of-life measures.
Collapse
Affiliation(s)
- Ida J Korfage
- Department of Public Health, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
| | | | | | | | | |
Collapse
|
9
|
Korfage IJ, Hak T, de Koning HJ, Essink-Bot ML. Patients' perceptions of the side-effects of prostate cancer treatment--a qualitative interview study. Soc Sci Med 2006; 63:911-9. [PMID: 16798130 DOI: 10.1016/j.socscimed.2006.01.027] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2005] [Indexed: 11/25/2022]
Abstract
Primary prostate cancer treatment often results in suboptimal urinary, bowel and/or sexual function. These effects are not inevitable. After treatment patients typically report high health related quality of life (QoL) scores. This discrepancy between disease-specific and generic results raises the question which meaning side effects actually have to patients. In a qualitative study we explored two mechanisms which could possibly explain the discrepancy: insensitivity of generic QoL measures to these specific symptoms and adaptation to changed health (response shift). In semi-structured interviews with 33 prostate cancer patients in the Netherlands we collected data on their opinions regarding health and QoL, we observed how respondents behaved when completing health status and QoL questionnaires, and solicited comments on a QoL questionnaire, its items, and its content validity. We observed that patients trivialized sexual (dys) function referring to old age. We found that while they might consider sexual, urinary, and bowel dysfunctions as problems, they did not take such dysfunctions into account when completing QoL measures because they did not view these dysfunctions as aspects of health. This finding reveals a so far unidentified cause of the insensitivity of generic measures of health status. Furthermore, response shift appeared to be present: many patients accepted the side effects as inevitable consequences of having been treated for prostate cancer, a condition they perceived as life threatening. We conclude that generic QoL measures cannot reveal the impact of sexual, urinary and bowel dysfunctions on patients because such dysfunctions are not perceived as health problems. By presenting these findings we want to draw attention to issues that complicate QoL assessments in general and in prostate cancer patients in particular.
Collapse
Affiliation(s)
- Ida Joanna Korfage
- Department of Public Health, ErasmusMC, University Medical Center Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, Netherlands.
| | | | | | | |
Collapse
|
10
|
Abstract
QOL outcomes have become an integral component of many clinical oncology trials. Much work has been performed testing the validity and reliability of Q OL instruments. The current challenge is to understand better the clinical relevance of QOL research in oncology. QOL studies should focus on phase III trials with clear hypotheses that can lead to clinically meaningful interventions.
Collapse
Affiliation(s)
- Farzan Siddiqui
- Department of Radiation Oncology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, and Department of Radiation Oncology, Boston University Medical Center, MA, USA
| | | | | |
Collapse
|
11
|
Blank TO, Bellizzi KM. After prostate cancer: Predictors of well-being among long-term prostate cancer survivors. Cancer 2006; 106:2128-35. [PMID: 16607648 DOI: 10.1002/cncr.21865] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND Despite growing numbers of prostate cancer (PCa) survivors, to the authors' knowledge there is little research regarding how personality, coping, and treatment influence men's psychologic well-being, as distinct from the often-studied functional, health-related quality of life. The purpose of this study was to examine how hope, optimism, use of coping strategies, and primary treatment predict well-being, positive and negative affect, impact, depression, and adaptive changes among PCa survivors. METHODS A questionnaire tapping personality, primary treatment, and coping strategy predictor variables and outcome variables of both positive and negative aspects of well-being was sent to 1-8-year PCa survivors. The final sample included 490 men. RESULTS Basic univariate analyses demonstrated that the men reported being happy, hopeful, and positive, with low levels of negative outcomes. Regression analyses demonstrated that positive outcomes were influenced primarily by personality. Negative outcomes were found to be affected by both personality and coping strategies. Adaptive changes were the only ones found to be significantly affected by primary treatment. CONCLUSIONS Although longer-term survivorship of PCa does not appear to be a highly traumatic experience, personality factors and the use of coping strategies years after treatment were found to introduce variability to well-being in complex ways, differing in relation to positive and negative outcomes. Clinical attention should be given to how the experience of cancer fits within the larger context of an individual's attitudes, choices, and coping strategy orientation. Cancer 2006. (c) 2006 American Cancer Society.
Collapse
Affiliation(s)
- Thomas O Blank
- Human Development and Family Studies, School of Family Studies, University of Connecticut, Storrs, Connecticut 06269-2058, USA.
| | | |
Collapse
|
12
|
Bradley CJ, Neumark D, Luo Z, Bednarek H, Schenk M. Employment outcomes of men treated for prostate cancer. J Natl Cancer Inst 2005; 97:958-65. [PMID: 15998948 DOI: 10.1093/jnci/dji171] [Citation(s) in RCA: 102] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Some organizations recommend prostate cancer screening for men younger than age 65 years, many of whom will be employed when they are diagnosed and treated for prostate cancer. Yet little is known about how prostate cancer and its treatment affect men's employment status. Consequently, we explored employment outcomes 6 and 12 months after the diagnosis of prostate cancer. METHODS We collected data from a prospective, population-based, longitudinal cohort of 267 men aged 30-65 years who had been diagnosed with prostate cancer and compared their likelihood of employment to that of men in two population-based control groups of 283 and 256 men without prostate cancer. The study outcomes were, among all participants, employment status and, among patients with prostate cancer, reasons why they remained employed, reasons why their weekly hours worked changed, and work-related disabilities. We predicted employment using probit regression models. In addition, we tested differences between the samples with two-sample Wilcoxon rank sum tests and chi-square tests. All statistical tests were two-sided. RESULTS Patients with prostate cancer were 10 percentage points (95% confidence interval [CI] = 2.50 to 17.51 percentage points; P = .009) less likely to be working 6 months after their diagnosis than men without prostate cancer. However, at 12 months after diagnosis, the likelihood of employment for prostate cancer patients and control subjects was not statistically significantly different (P = .771). Some patients reported that cancer and its treatment interfered with their ability to perform physical and cognitive tasks at work 12 months after diagnosis. For example, 26% (95% CI = 18.51% to 33.87%) of men (33 patients) reported that cancer interfered with their ability to perform tasks that involved physical effort. CONCLUSIONS Prostate cancer and its treatment appear to have an impact on employment.
Collapse
Affiliation(s)
- Cathy J Bradley
- Department of Health Administration, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298-0203, USA.
| | | | | | | | | |
Collapse
|
13
|
Interstitial photodynamic therapy for prostate cancer: a developing modality. Photodiagnosis Photodyn Ther 2004; 1:123-36. [DOI: 10.1016/s1572-1000(04)00037-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
14
|
Hollenbeck BK, Dunn RL, Wei JT, Sandler HM, Sanda MG. Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer. Curr Urol Rep 2004; 5:212-9. [PMID: 15161570 DOI: 10.1007/s11934-004-0039-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Each of the three most common contemporary treatments for localized prostate cancer, radical prostatectomy, external beam radiotherapy, and brachytherapy, can have adverse effects on sexual health. Sexual health outcome can be improved by treatment-specific factors, such as the use of nerve-sparing technique during radical prostatectomy, or worsened by the use of androgen deprivation before external beam radiotherapy or brachytherapy. Contemporary studies that have used validated questionnaires to evaluate multiple components of patient-reported sexuality following prostate cancer treatments provide benchmarks of sexual outcome expectations that are of interest to patients selecting their prostate cancer treatment.
Collapse
Affiliation(s)
- Brent K Hollenbeck
- Division of Urology, Beth Israel-Deaconess Medical Center, Rabb 440, 330 Brookline Avenue, Boston, MA 02215, USA
| | | | | | | | | |
Collapse
|